NSAH?
CAS No. 1099592-35-4
NSAH?( 2-hydroxy-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide )
Catalog No. M22882 CAS No. 1099592-35-4
NSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 58 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 205 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 500MG | 1134 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSAH?
-
NoteResearch use only, not for human use.
-
Brief DescriptionNSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition.
-
DescriptionNSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition. A 2.66- resolution crystal structure of NSAH in complex with hRRM1 demonstrates that NSAH functions by binding at the catalytic site (C-site) where it makes both common and unique contacts with the enzyme compared with NDP substrates. Importantly, the IC for NSAH is within twofold of gemcitabine for growth inhibition of multiple cancer cell lines, while demonstrating little cytotoxicity against normal mobilized peripheral blood progenitor cells. NSAH depresses dGTP and dATP levels in the dNTP pool causing S-phase arrest, providing evidence for RR inhibition in cells.NSAH (0-10 μM, 2, 6, 24, or 72 h) exhibits potent anti-tumor activity in 3 cancer cell lines.
-
In VitroNSAH depresses dGTP and dATP levels in the dNTP pool causing S-phase arrest, providing evidence for RR inhibition in cells.NSAH (0-10 μM, 2, 6, 24, or 72 h) exhibits potent anti-tumor activity in 3 cancer cell lines.NSAH blocks S-phase progression well to the extent and timing of the decreases in dATP and dGTP. Cell Viability Assay Cell Line:MDA-231, HCT116 and Panc1 cancer cell lines.Concentration:0-10 μM.Incubation Time:2, 6, 24, or 72 h.Result:Resulted in IC50 values ranging from 220 to 500 nM.
-
In Vivo——
-
Synonyms2-hydroxy-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorRR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1099592-35-4
-
Formula Weight306.3
-
Molecular FormulaC18H14N2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:62.5 mg/mL (204.03 mM; Need ultrasonic)
-
SMILESO=C(C1=CC=CC=C1O)N/N=C/C2=C3C=CC=CC3=CC=C2O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Md Faiz Ahmad, et al. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246.
molnova catalog
related products
-
Rifapentine
Rifapentine is an antibiotic drug used in the treatment of tuberculosis.
-
SR 11302
SR 11302 is an inhibitor of activator protein-1 (AP-1).
-
Fialuridine
Fialuridine is a DNA-directed DNA polymerase inhibitor potentially for the treatment of HBV infection with potent activity against hepatitis B virus in vitro and in vivo.
Cart
sales@molnova.com